

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Muthiah Manoharan, Martin A. Maier, Thazha P. Prakash and Kallanthottathil

Gopalan Rajeev

Application No.: 09/996,292

Filing Date: November 28, 2001

Confirmation No.: 3997

Group Art Unit: 1635

Examiner: McGarry, Sean

For: NUCLEASE RESISTANT CHIMERIC OLIGONUCLEOTIDES

EXPRESS MAIL LABEL NO: EL999300250US DATE OF DEPOSIT: October 22, 2004

Mail Stop SEQUENCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825

Ш	contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.
	I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.
	I hereby state that the submission filed in accordance with 37 CFR §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.
\boxtimes	I hereby state that the amendments, made in accordance with 37 CFR §1.825(a), included in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at Figure 1 and pages 126 and 128. I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.
\boxtimes	I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.
	I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(d), contains identical data to that originally filed.

Date: October 22, 2004

Jane E. Inglese, Ph.D. Registration No. 48,444

Woodcock Washburn LLP One Liberty Place - 46th Floor Philadelphia PA 19103 Telephone: (215) 568-3100

Facsimile: (215) 568-3439

© 2004 WW

DOCKET NO.: ISIS-4804

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Muthiah Manoharan, Martin A. Maier, Thazha P. Prakash and Kallanthottathil

Gopalan Rajeev

Application No.: 09/996,292

Filing Date: November 28, 2001

996,292 Group Art Unit: 1635

Confirmation No.: 3997

Examiner: McGarry, Sean

NUCLEASE RESISTANT CHIMERIC OLIGONUCLEOTIDES

EXPRESS MAIL LABEL NO: EL999300250US

DATE OF DEPOSIT: October 22, 2004

№ EL999300250US

Mail Stop SEQUENCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURE

In response to the "Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" dated September 27, 2004, a response to which is due October 27, 2004, enclosed herewith is:

\boxtimes	Statement to Support Filing and Submission in Accordance with 37 CFR §§1.821 through 1.825;
\boxtimes	Substitute pages of the Sequence Listing;
\boxtimes	Substitute copy of the computer readable form of amended Sequence Listing;
\boxtimes	Amendment Directing Entry of Sequence Listing into Specification is attached
\boxtimes	Copy of Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
	Other:

1635)

-	s hereby made under 37 CFR § 1.136(a) to extend the	time for
response t	o the Notice to File Missing Parts of Application of	to and
through months:	, comprising an extension of the shortened period	of

	SMALL	ENTITY		SMALL FITY
	RATE	FEE	RATE	FEE
ONE MONTH EXTENSION OF TIME	\$55	\$	\$110	\$
☐ TWO MONTH EXTENSION OF TIME	\$215	\$	\$430	\$
☐ THREE MONTH EXTENSION OF TIME	\$490	\$	\$980	\$
☐ FOUR MONTH EXTENSION OF TIM	\$765	\$	\$1530	\$
☐ FIVE MONTH EXTENSION OF TIME	\$1040	\$	\$2080	\$
TOTAL FEE DUE		\$0		\$0

Applicant(s) has/have not been notified that the requested extension will not be permitted. The present application is not involved in an interference declared pursuant to 37 CFR § 1.207.

Total fee required **§0.00**

The Commission is hereby authorized to charge payment of the above fees associated with this communication or credit any overpayment to Deposit Account No. 23-3050.
This sheet is attached in duplicate.

Date: October 22, 2004

Jane E. Inglese, Ph.D. Registration No. 48,444

Woodcock Washburn LLP One Liberty Place - 46th Floor Philadelphia PA 19103 Telephone: (215) 568-3100

Facsimile: (215) 568-3439

© 2004 WW

Application No.: 09/996,292

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEO TO ENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. ∋ 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicants attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	2. This application does not contain, as a separate part of the disclosure on paper copy, a ASequence Listing≅ as required by 37 C.F.R. 1.821(c).
	3. A copy of the ASequence Listing≅ in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the Sequence Listing in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up Raw Sequence Listing.
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the ASequence Listing≅ is not the same as the computer readable from of the ASequence Listing≅ as required by 37 C.F.R. 1.821(e).
	7. Other:
Ap	plicant Must Provide:
X	An initial or <u>substitute</u> computer readable form (CRF) copy of the Sequence Listing. (If the unidentified sequences are not provided on the CRF)
X	An initial or <u>substitute</u> paper copy of the Sequence Listing, as well as an amendment directing its entry into the specification. (If the unidentified sequences are not provided in the paper copy)
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d). (If a new paper and/or CRF are required)
Foi	r questions regarding compliance to these requirements, please contact:
Fo	r Rules Interpretation, call (703) 308-4216 r CRF Submission Help, call (703) 308-4212 tentIn Software Program Support Technical Assistance
	To Purchase Patentin Software703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY